A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease

Part of paid clinical trials in Nutley, New Jersey.

Sponsor
Eisai Inc.
Study ID
NCT07864623
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • No Intervention — OTHER
    This is a non-interventional study.

Study Details

The primary purpose of this study is to evaluate the efficacy of LEQEMBI in participants with early Alzheimer's disease (AD) indicated per Canada Product Monograph (APOE4 non-carriers and heterozygotes; indicated population) compared with placebo (PBO)-treated participants from BAN2401-G000-301 (Study 301) Core study on change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment.

Key Dates

First listed
Oct 8, 2026
Start date
Oct 30, 2026
Status verified
Sep 2026
Primary completion
Aug 31, 2029
Completion
Aug 31, 2029

Study Design

Enrollment
270 participants (estimated)

Arms

  • Arm: Participants Treated With Lecanemab

Primary Outcome Measure

Change from Baseline in the CDR-SB [ Time Frame: Baseline, 18 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Eisai Trial Site #1NutleyNew Jersey07110-

Find similar trials in Nutley, NJ

Nationwide
Alzheimer's disease trialsNeurology trialsDementia care trialsBrain disorders trialsGeriatrics trials
By condition
Alzheimer's disease
By specialty
NeurologyDementia careBrain disordersGeriatrics
By research site
Eisai Trial· Nutley, NJ

Related Studies